EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacogenetic hSLCO1B1*14 ‐Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response

Felicia Gooden iD, Brennan D Meier, Griffin D Shaffer iD, Kim Gibson, Paul Toren, Nieko C Punt iD, Sandhya Subash iD, Dilip K Singh iD, Bhagwat Prasad iD, Laura B Ramsey iD, Zachary L Taylor iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Felicia Gooden und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology, and Neurobiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Experimental, Arthritis, Juvenile, Liver-Specific Organic Anion Transporter 1. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ASCPT Darrell Abernethy Early-Stage Investigator Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease that negatively affects ~100,000 children under the age of 16 in the United States. About ~30% of these patients fail first‐line drug therapy with low‐dose methotrexate (MTX) due to poor tolerability or lack of efficacy. The SLCO1B1*14 allele is associated with increased MTX clearance and has been linked to reduced overall drug exposure and nonresponse to MTX in JIA patients. Herein, we describe transgenic hSLCO1B1*14 and hSLCO1B1*1 DBA1/J mSlco1b2 knock‐out mice, which we used to assess arthritic response to MTX using the collagen‐induced arthritis model. Mass spectrometry‐based proteomics analysis revealed that OATP1B1 protein abundance was 2.1‐fold higher in hSLCO1B1*14 mice compared to hSLCO1B1*1 mice. Following treatment with 1 mg/kg MTX for 3 weeks, hSLCO1B1*14 mice exhibited a 39% increase in median arthritic disease burden ( p = 0.02) and a 22% reduction in MTX AUC ( p = 0.14) compared to hSLCO1B1*1 mice. Pharmacokinetic modeling estimated that the hSLCO1B1*14 mice would need a 30% higher dose to equalize exposure and response to hSLCO1B1*1 mice. When hSLCO1B1*14 mice received 1.3 mg/kg MTX, the arthritic disease burden and overall MTX exposure were less than the 1 mg/kg MTX in hSLCO1B1*1 mice, reinforcing that differences in MTX elimination and therapeutic response can be accounted for by using pharmacogenetic‐guided dosing of MTX in JIA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateArthritis, ExperimentalArthritis, JuvenileLiver-Specific Organic Anion Transporter 1Antirheumatic AgentsAnimalsMiceMice, KnockoutHumansDisease Models, AnimalMice, TransgenicMaleDose-Response Relationship, DrugMice, Inbred DBAFemale

Stichwörter der Autor:innen

animal/mouse/rodentmodelingpharmacogeneticspharmacokineticspreclinicalsimulationtranslational pharmacology

Substanzen

MethotrexateLiver-Specific Organic Anion Transporter 1Antirheumatic Agents

Autor:innen und Institutionen

  • Department of Pharmacology, Physiology, and Neurobiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Medical Sciences, University of Cincinnati, Cincinnati, Ohio, USA.
  • Mass Spectrometry & Bioanalysis Core, Children's Mercy Hospital, Kansas City, Missouri, USA.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Medimatics, Maastricht, the Netherlands.

ORCID-Profile: Felicia Gooden, Griffin D Shaffer, Nieko C Punt, Sandhya Subash, Dilip K Singh, Bhagwat Prasad, Laura B Ramsey, Zachary L Taylor

Förderung

  • ASCPT Darrell Abernethy Early-Stage Investigator Award

Zitieren

APA

Gooden, F., Meier, B. D., Shaffer, G. D., Gibson, K., Toren, P., Punt, N. C., Subash, S., Singh, D. K., Prasad, B., Ramsey, L. B., & Taylor, Z. L. (2026). Pharmacogenetic hSLCO1B1*14 ‐Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response. Clinical and Translational Science. https://doi.org/10.1111/cts.70449

Vancouver

Gooden F, Meier BD, Shaffer GD, Gibson K, Toren P, Punt NC, et al. Pharmacogenetic hSLCO1B1*14 ‐Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response. Clinical and Translational Science. 2026. doi:10.1111/cts.70449

BibTeX
@article{Gooden2026,
  author = {Gooden, Felicia and Meier, Brennan D and Shaffer, Griffin D and Gibson, Kim and Toren, Paul and Punt, Nieko C and Subash, Sandhya and Singh, Dilip K and Prasad, Bhagwat and Ramsey, Laura B and Taylor, Zachary L},
  title = {Pharmacogenetic hSLCO1B1*14 ‐Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70449}
}
Kostenlos starten →